Natixis Advisors L.P. Sells 147,093 Shares of Kenvue Inc. (NYSE:KVUE)

Natixis Advisors L.P. trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 8.1% in the 4th quarter, Holdings Channel reports. The fund owned 1,676,741 shares of the company’s stock after selling 147,093 shares during the quarter. Natixis Advisors L.P.’s holdings in Kenvue were worth $36,100,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Commonwealth Equity Services LLC bought a new position in Kenvue in the third quarter worth $5,053,000. Cambridge Investment Research Advisors Inc. bought a new position in Kenvue in the third quarter worth $1,809,000. Kingswood Wealth Advisors LLC bought a new position in Kenvue in the third quarter worth $215,000. FinTrust Capital Advisors LLC acquired a new position in Kenvue during the third quarter worth $66,000. Finally, Raymond James & Associates lifted its holdings in shares of Kenvue by 635.4% during the third quarter. Raymond James & Associates now owns 2,653,777 shares of the company’s stock valued at $53,288,000 after acquiring an additional 2,292,926 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

KVUE traded up $0.08 on Friday, hitting $19.20. 15,941,057 shares of the company were exchanged, compared to its average volume of 15,351,688. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The stock’s fifty day moving average is $19.82 and its 200-day moving average is $20.11. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue’s quarterly revenue was down 2.7% compared to the same quarter last year. As a group, research analysts forecast that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.17%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KVUE. The Goldman Sachs Group initiated coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. William Blair assumed coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Sanford C. Bernstein began coverage on shares of Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. Finally, Royal Bank of Canada dropped their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.